Filing Details
- Accession Number:
- 0000899243-18-003749
- Form Type:
- 5
- Zero Holdings:
- No
- Publication Time:
- 2018-02-13 21:27:08
- Reporting Period:
- 2017-12-31
- Accepted Time:
- 2018-02-13 21:27:08
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1629137 | Global Blood Therapeutics Inc. | GBT | Pharmaceutical Preparations (2834) | 274825712 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1730866 | Ann Lesley Calhoun | C/O Global Blood Therapeutics, Inc. 171 Oyster Point Blvd., Suite 300 South San Francisco CA 94080 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2017-08-02 | 1,552 | $27.23 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2017-09-01 | 300 | $0.00 | 300 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-09-01 | 113 | $30.30 | 187 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2017-03-01 | 3,600 | $0.00 | 3,600 | $29.75 |
| Common Stock | Restricted Stock Units | Acquisiton | 2017-03-01 | 2,400 | $0.00 | 2,400 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2017-09-01 | 300 | $0.00 | 300 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 3,600 | 2026-02-28 | No | 4 | A | Direct | |
| 2,400 | No | 4 | A | Direct | ||
| 2,100 | No | 4 | M | Direct |
Footnotes
- Includes 1,552 shares acquired under the Issuer's Employee Stock Purchase Plan on July 31, 2017 in a transaction exempt under Rule 16b-3.
- Each restricted stock unit represents a contingent right to receive one share of GBT common stock.
- The Stock Option becomes exercisable in sixteen equal quarterly installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- The Restricted Stock Units vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Billionaire Hedge Funds
